Antimicrobial Agents Practice Questions

Q: Which of the following drugs is NOT used in the treatment of extended drug resistance?

Rifampicin. The question focuses on the definitions and treatment protocols for drug-resistant tuberculosis (TB), a high-yield topic for NEET-PG. ### **Explanation of the Correct Answer** **A. Rifampicin** is the correct answer because, by definition, **Extensively Drug-Resistant TB (XDR-TB)** is defined as TB that is resistant to at least **Isoniazid and Rifampicin** (MDR-TB), plus resistance to any fluoroquinolone and at least one of the three injectable second-line drugs (Amikacin, Kanamycin, or Capreomycin). Since Rifampicin resistance is a prerequisite for the diagnosis of XDR-TB, it is inherently ineffective and **not used** in its treatment. ### **Analysis of Incorrect Options** * **B. Isoniazid:** While XDR-TB is resistant to standard doses of Isoniazid, **High-dose Isoniazid** is sometimes included in WHO-recommended shorter regimens for drug-resistant TB if specific mutations (like *inhA* promoter mutations) suggest low-level resistance that can be overcome. * **C. Moxifloxacin:** This is a later-generation fluoroquinolone. While XDR-TB is resistant to "a" fluoroquinolone, newer agents like **high-dose Moxifloxacin** or Gatifloxacin were historically part of salvage regimens, though BPaL (Bedaquiline, Pretomanid, Linezolid) is now preferred. * **D. Capreomycin:** This is a cyclic peptide (injectable second-line drug). It was a mainstay in the treatment of MDR-TB and used in XDR-TB cases where sensitivity was still preserved to at least one injectable agent. ### **NEET-PG High-Yield Pearls** * **MDR-TB:** Resistance to Isoniazid (H) + Rifampicin (R). * **Pre-XDR-TB:** MDR-TB + resistance to any Fluoroquinolone. * **XDR-TB (New WHO Definition):** MDR-TB + resistance to any Fluoroquinolone + resistance to at least one Group A drug (**Bedaquiline or Linezolid**). * **Drug of Choice for XDR-TB:** The **BPaL regimen** (Bedaquiline, Pretomanid, and Linezolid) is currently the standard of care.

Q: In antiretroviral therapy, which of the following drugs should not be combined with Zidovudine?

Stavudine. ### Explanation The correct answer is **Stavudine (D)**. **Why Stavudine is the correct answer:** Both **Zidovudine (AZT)** and **Stavudine (d4T)** are Nucleoside Reverse Transcriptase Inhibitors (NRTIs) that act as **thymidine analogs**. To become active, they must be phosphorylated by the same intracellular enzyme, **thymidine kinase**. When administered together, they compete for this enzyme. Zidovudine has a higher affinity for thymidine kinase and effectively inhibits the phosphorylation (activation) of Stavudine. This results in a **pharmacodynamic antagonism**, rendering the combination clinically ineffective and increasing the risk of toxicity without therapeutic benefit. **Analysis of Incorrect Options:** * **A. Lamivudine (3TC):** This is a cytosine analog. It uses different phosphorylation pathways and is the most common partner for Zidovudine (e.g., the Combivir regimen) due to synergistic effects. * **B. Nevirapine:** This is a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). It has a completely different mechanism of action (binding directly to the enzyme) and is frequently combined with Zidovudine in NNRTI-based regimens. * **C. Didanosine (ddI):** This is a purine (adenosine) analog. It does not compete with Zidovudine for activation and was historically used in dual NRTI combinations. **High-Yield Clinical Pearls for NEET-PG:** * **Zidovudine (AZT) Side Effects:** Macrocytic anemia (most common) and bone marrow suppression. It is the drug of choice for preventing mother-to-child transmission (MTCT) during labor. * **Stavudine (d4T) Side Effects:** Highest risk of peripheral neuropathy and lipodystrophy among NRTIs. * **Mnemonic:** Remember **"Z"** and **"S"** (Zidovudine and Stavudine) are both **Thymidine** analogs—they "Stay" away from each other to avoid competition.

Q: All of the following are useful in the management of severe Clostridium difficile infection, except?

Neomycin enema. **Explanation:** The management of *Clostridioides difficile* infection (CDI) focuses on agents that reach therapeutic concentrations in the colon and possess activity against anaerobic gram-positive bacilli. **Why Neomycin is the correct answer (Except):** Neomycin is an aminoglycoside. Aminoglycosides are strictly aerobic in their mechanism of action (requiring oxygen for uptake into the bacterial cell) and are **ineffective against anaerobes** like *C. difficile*. Furthermore, neomycin is highly nephrotoxic and ototoxic if absorbed, and its use is generally limited to bowel preparation or hepatic encephalopathy. It has no role in treating CDI. **Analysis of other options:** * **Oral Vancomycin:** This is the **first-line treatment** for severe CDI. It is not absorbed systemically, ensuring high intraluminal concentrations directly at the site of infection. * **IV Metronidazole:** While oral metronidazole is used for mild cases, IV metronidazole is added to oral vancomycin in **fulminant/complicated** cases (e.g., ileus or shock) because it reaches the inflamed colon via biliary secretion and systemic circulation. * **Tigecycline:** This is a glycylcycline with broad-spectrum activity, including potent anti-anaerobic properties. It is considered a **rescue therapy** for refractory or severe CDI when standard treatments fail. **NEET-PG High-Yield Pearls:** 1. **Drug of Choice:** Oral Vancomycin or Fidaxomicin (Fidaxomicin has lower recurrence rates). 2. **Metronidazole:** Only antibiotic used **IV** for CDI (Vancomycin must be oral/rectal). 3. **Bezlotoxumab:** A monoclonal antibody against Toxin B used to prevent recurrence. 4. **Fecal Microbiota Transplant (FMT):** Indicated for multiple recurrences of CDI.

Q: What is the drug of choice for non-gonococcal urethritis?

Doxycycline. **Explanation:** **Non-gonococcal urethritis (NGU)** is most commonly caused by *Chlamydia trachomatis*, followed by *Mycoplasma genitalium*. 1. **Why Doxycycline is correct:** According to the latest CDC and WHO guidelines, **Doxycycline (100 mg twice daily for 7 days)** is the first-line drug of choice for NGU. It is a bacteriostatic tetracycline that inhibits protein synthesis by binding to the 30S ribosomal subunit. It is highly effective against intracellular organisms like *Chlamydia*. While Azithromycin (1g single dose) was previously preferred for compliance, Doxycycline is now favored due to superior efficacy against *Mycoplasma genitalium* and rectal chlamydial infections. 2. **Why the other options are incorrect:** * **Tetracycline:** While in the same class, it requires four-times-daily dosing and has more gastrointestinal side effects and lower bioavailability compared to Doxycycline. * **Ciprofloxacin:** This is a fluoroquinolone. While it has some activity against Gram-negative bacteria, it is not the primary choice for NGU due to rising resistance and inferior efficacy against *Chlamydia* compared to tetracyclines. * **Ceftriaxone:** This is a third-generation cephalosporin and the **drug of choice for Gonococcal urethritis** (Gonorrhea). It is ineffective against *Chlamydia* because *Chlamydia* lacks a traditional peptidoglycan cell wall. **High-Yield Clinical Pearls for NEET-PG:** * **Syndromic Management (Kit 1):** In India, under the NACO guidelines, the Grey Kit (Azithromycin 1g + Cefixime 400mg) is used for the syndromic management of urethral discharge to cover both Gonorrhea and NGU. * **Pregnancy:** Doxycycline is contraindicated in pregnancy (teratogenic - causes bone/teeth discoloration). In pregnant patients with NGU, **Azithromycin** is the drug of choice. * **Co-infection:** Always treat for both Gonorrhea and Chlamydia if the specific pathogen is not identified.

Q: Which antimicrobial drug is used orally exclusively for urinary tract infections or bacterial diarrheas?

Nalidixic acid. **Explanation:** **Nalidixic acid** is the correct answer because it is a first-generation quinolone with a unique pharmacokinetic profile. When taken orally, it is rapidly absorbed but undergoes extensive metabolism and rapid renal excretion. Consequently, it fails to achieve therapeutic systemic concentrations in the blood or tissues but reaches **high bactericidal concentrations in the urine**. Additionally, its unabsorbed portion remains active in the gut. Therefore, its clinical utility is strictly limited to **uncomplicated Urinary Tract Infections (UTIs)** and **bacillary dysentery (bacterial diarrhea)**. **Analysis of Incorrect Options:** * **A. Bacampicillin:** This is a prodrug of Ampicillin (a penicillin). It achieves high systemic levels and is used for various infections, including respiratory tract infections and otitis media, not just UTIs. * **C. Azithromycin:** A macrolide with extensive tissue distribution and a long half-life. It is used systemically for pneumonia, typhoid, and STDs (Chlamydia). * **D. Pefloxacin:** A second-generation fluoroquinolone. Unlike nalidixic acid, it achieves excellent systemic distribution and can cross the blood-brain barrier; it is used for systemic infections like enteric fever. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** Nalidixic acid inhibits **DNA Gyrase** (Topoisomerase II), preventing bacterial DNA replication. * **Resistance:** Resistance develops rapidly during treatment; hence, it has been largely replaced by newer fluoroquinolones (e.g., Ciprofloxacin). * **Contraindication:** It should be avoided in patients with **G6PD deficiency** as it can precipitate hemolysis. * **Side Effects:** It is known to cause visual disturbances and can increase intracranial pressure (pseudotumor cerebri) in children.

Q: Following an appendectomy, a 28-year-old man is placed on ceftizoxime sodium. This antibiotic is unlikely to be effective against which of the following?

Pseudomonas. **Explanation:** Ceftizoxime is a **third-generation cephalosporin**. To answer this question correctly, one must understand the specific spectrum of activity within the third-generation class, particularly the distinction between those that cover *Pseudomonas* and those that do not. **Why Pseudomonas is the Correct Answer:** While third-generation cephalosporins have expanded Gram-negative coverage compared to earlier generations, **Ceftizoxime lacks activity against *Pseudomonas aeruginosa***. In the third-generation class, only **Ceftazidime** and **Cefoperazone** possess reliable anti-pseudomonal activity. **Analysis of Incorrect Options:** * **Staphylococcus aureus:** Third-generation cephalosporins maintain some activity against methicillin-susceptible *S. aureus* (MSSA), though they are generally less potent than first-generation agents (like Cefazolin). * **Neisseria gonorrhoeae:** This class is highly effective against Gram-negative cocci. Ceftriaxone is the drug of choice, but Ceftizoxime also maintains excellent activity against *Neisseria* species. * **Bacteroides fragilis:** Ceftizoxime is unique among many third-generation cephalosporins because it possesses notable **anaerobic activity**, making it effective against *B. fragilis*. This is why it is often used in intra-abdominal infections like appendicitis. **High-Yield NEET-PG Pearls:** 1. **Anti-pseudomonal Cephalosporins:** Remember the "3rd and 4th" rule: **Ceftazidime, Cefoperazone** (3rd gen), and **Cefepime** (4th gen). 2. **Anaerobic Coverage:** Most cephalosporins lack anaerobic coverage. Exceptions include **Cefoxitin, Cefotetan** (2nd gen), and **Ceftizoxime** (3rd gen). 3. **Excretion:** Unlike Ceftriaxone (biliary excretion), Ceftizoxime is primarily excreted by the kidneys.

Q: A 30-year-old pregnant woman develops tuberculosis. Which of the following antitubercular drugs should be avoided during pregnancy?

Streptomycin. ### Explanation **Correct Option: C. Streptomycin** **Why it is correct:** Streptomycin is an aminoglycoside that is strictly contraindicated during pregnancy (FDA Category D). It crosses the placental barrier and is known to be **ototoxic** to the fetus. Exposure during gestation can lead to permanent **congenital deafness** (damage to the 8th cranial nerve) and potential nephrotoxicity in the developing fetus. **Why the other options are incorrect:** * **A. Isoniazid (INH):** Considered safe in pregnancy. However, because pregnancy increases the risk of peripheral neuropathy, it must always be co-administered with **Pyridoxine (Vitamin B6)**. * **B. Rifampicin:** Considered safe and is a core component of the RNTCP/WHO regimen for pregnant women. It may rarely cause neonatal hypoprothrombinemia, so Vitamin K prophylaxis is recommended at birth. * **D. Ethambutol:** Considered the safest of the first-line drugs in pregnancy with no documented teratogenic effects. **NEET-PG High-Yield Pearls:** 1. **Standard Regimen:** The WHO and National Guidelines recommend the standard 2HRZE/4HRE regimen for pregnant women. Only Streptomycin is excluded from the first-line list. 2. **Pyrazinamide (PZA):** While some older texts debated its safety, the WHO and Indian national guidelines now include PZA in the intensive phase for pregnant patients. 3. **Second-line Drugs to Avoid:** Beyond Streptomycin, other aminoglycosides (Kanamycin, Amikacin) and **Fluoroquinolones** (due to cartilage damage) should generally be avoided unless the benefit outweighs the risk (e.g., MDR-TB). 4. **Breastfeeding:** All first-line antitubercular drugs are compatible with breastfeeding as they are excreted in negligible amounts in breast milk.

Q: What is the DOC for management of visceral Leishmaniasis?

Liposomal Amphotericin B. **Liposomal Amphotericin B** is currently the **Drug of Choice (DOC)** for Visceral Leishmaniasis (Kala-azar), especially in the Indian subcontinent [1]. The underlying medical concept relies on its superior efficacy (cure rates >95%) [1] and significantly lower toxicity compared to conventional agents. The liposomal formulation allows the drug to be specifically taken up by the **reticuloendothelial system (macrophages)** in the liver and spleen—the exact site where *Leishmania donovani* resides—thereby increasing therapeutic index and reducing nephrotoxicity. **Analysis of Incorrect Options:** * **Parenteral Sodium Stibogluconate (SSG):** Formerly the first-line treatment, it is no longer the DOC due to widespread **antimonial resistance** (especially in Bihar, India) [2] and severe side effects like cardiotoxicity and pancreatitis. * **Miltefosine:** This is the first **effective oral drug** for Kala-azar [2]. While highly useful for mass treatment, it is not the primary DOC due to teratogenicity (requires strict contraception) and increasing reports of treatment failure. * **Pentamidine:** Previously used as a second-line agent, it is now rarely used for Leishmaniasis due to significant toxicities, including irreversible diabetes mellitus and hypotension. **High-Yield Clinical Pearls for NEET-PG:** * **WHO Protocol:** A single dose of Liposomal Amphotericin B (10 mg/kg) is the preferred regimen in India. * **Post-Kala-azar Dermal Leishmaniasis (PKDL):** The DOC is also Miltefosine (for 12 weeks) or Amphotericin B. * **Mechanism of Amphotericin B:** It binds to **ergosterol** in the fungal/protozoal cell membrane, creating pores that lead to ion leakage and cell death.

Question 1

Which of the following drugs is NOT used in the treatment of extended drug resistance?

Accepted Answer

Rifampicin

Answer

Isoniazid

Answer

Moxifloxacin

Answer

Capreomycin

Question 2

In antiretroviral therapy, which of the following drugs should not be combined with Zidovudine?

Accepted Answer

Stavudine

Answer

Lamivudine

Answer

Nevirapine

Answer

Didanosine

Question 3

All of the following are useful in the management of severe Clostridium difficile infection, except?

Accepted Answer

Neomycin enema

Answer

Oral vancomycin

Answer

IV metronidazole

Answer

Tigecycline

Question 4

What is the drug of choice for non-gonococcal urethritis?

Accepted Answer

Doxycycline

Answer

Tetracycline

Answer

Ciprofloxacin

Answer

Ceftriaxone

Question 5

Which antimicrobial drug is used orally exclusively for urinary tract infections or bacterial diarrheas?

Accepted Answer

Nalidixic acid

Answer

Bacampicillin

Answer

Azithromycin

Answer

Pefloxacin

Question 6

A 50-year-old male, on anti-tuberculosis medication for two months, presents with hearing problems. Which of the following mechanisms of action is most likely responsible for these symptoms?

Accepted Answer

Binds to the 30S ribosome subunit and inhibits the initiation complex

Answer

Inhibits DNA-dependent RNA polymerase

Answer

Inhibits the synthesis of mycolic acid

Answer

Inhibits the synthesis of arabinoglycan subunits

Question 7

Following an appendectomy, a 28-year-old man is placed on ceftizoxime sodium. This antibiotic is unlikely to be effective against which of the following?

Accepted Answer

Pseudomonas

Answer

Staphylococcus aureus

Answer

Neisseria gonorrhoeae

Answer

Bacteroides fragilis

Question 8

A 30-year-old pregnant woman develops tuberculosis. Which of the following antitubercular drugs should be avoided during pregnancy?

Accepted Answer

Streptomycin

Answer

Isoniazid (INH)

Answer

Rifampicin

Answer

Ethambutol

Question 9

Which drug is not used in chloroquine-resistant malaria?

Accepted Answer

Fluoroquinolones

Answer

Sulfadoxine–pyrimethamine

Answer

Quinine

Answer

Artemisinins

Question 10

What is the DOC for management of visceral Leishmaniasis?

Accepted Answer

Liposomal Amphotericin B

Answer

Parenteral Sodium stibogluconate

Answer

Miltefosine

Answer

Pentamidine

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?